Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

doi:10.1182/bloodadvances.2020002271

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Blood advances - 13 Oct 2020

Luque Paz Damien, Jouanneau-Courville Rébecca, Riou Jérémie, Ianotto Jean-Christophe, Boyer Françoise, Chauveau Aurélie, Renard Maxime, Chomel Jean-Claude, Cayssials Emilie, Gallego-Hernanz Maria-Pilar, Pastoret Cédric, Murati Anne, Courtier Frédéric, Rousselet Marie-Christine, Quintin-Roué Isabelle, Cottin Laurane, Orvain Corentin, Thépot Sylvain, Chrétien Jean-Marie, Delneste Yves, Ifrah Norbert, Blanchet Odile, Hunault-Berger Mathilde, Lippert Eric, Ugo Valérie

Abstract excerpt

Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with the most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis. The interval between diagnosis and leukemic evolution is highly variable, from a few years to >20 years. We performed a molecular evaluation of 49 leukemic transformations of PV and ET by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Eosinophilic Disorders and Syndromes

Share to Genomics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 33035330
DOI: 10.1182/bloodadvances.2020002271
PMCID: PMC7556129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.PMID 33035330Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic OptionsSemantic proximity Read ↗

Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.Semantic proximity Read ↗

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.Semantic proximity Read ↗

Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.Semantic proximity Read ↗

A molecular signature predicts hematologic evolution in polycythemia vera patients.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.Semantic proximity Read ↗

Genomic trajectory in leukemogenesis of myeloproliferative neoplasms: a case report.Semantic proximity Read ↗

From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study.Semantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasmSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.